B2M and Thrombocytopenia: Similarly, a higher proportion of patients in these groups had thrombocytopenia (platelets < 150 × 109/L) (P < 0.001), beta2microglobulin (B2M) levels >5.5 μg/ml (P = 0.03), and ISS stage III disease (P = 0.04).